Analysts Offer Insights on Healthcare Companies: Molina Healthcare (MOH), Zai Lab (ZLAB) and Guardant Health (GH)

TipRanks

Jun. 6, 2025, 05:40 AM

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Molina Healthcare (MOH – Research Report), Zai Lab (ZLAB – Research Report) and Guardant Health (GH – Research Report).

Confident Investing Starts Here:

Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter

Molina Healthcare (MOH)

In a report released yesterday, Stephen Baxter from Wells Fargo maintained a Buy rating on Molina Healthcare, with a price target of $372.00. The company’s shares closed last Thursday at $293.56.

According to TipRanks.com, Baxter is a 1-star analyst with an average return of -2.4% and a 34.6% success rate. Baxter covers the Healthcare sector, focusing on stocks such as Community Health, Universal Health, and Tenet Healthcare.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Molina Healthcare with a $371.78 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Zai Lab (ZLAB)

Bank of America Securities analyst David Li reiterated a Hold rating on Zai Lab today and set a price target of $38.20. The company’s shares closed last Thursday at $36.54, close to its 52-week high of $39.77.

Li has an average return of 17.5% when recommending Zai Lab.

According to TipRanks.com, Li is ranked #7194 out of 9607 analysts.

Currently, the analyst consensus on Zai Lab is a Strong Buy with an average price target of $48.40.

Guardant Health (GH)

In a report released today, Subbu Nambi from Guggenheim reiterated a Buy rating on Guardant Health, with a price target of $56.00. The company’s shares closed last Thursday at $48.41, close to its 52-week high of $50.89.

According to TipRanks.com, Nambi has 0 stars on 0-5 stars ranking scale with an average return of -9.0% and a 40.0% success rate. Nambi covers the Healthcare sector, focusing on stocks such as Nautilus Biotechnolgy, Castle Biosciences, and Twist Bioscience.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Guardant Health with a $60.71 average price target, a 26.9% upside from current levels. In a report issued on May 30, Craig-Hallum also maintained a Buy rating on the stock.

Read More on MOH:

Disclaimer & Disclosure Report an Issue